1 March 2023 in Personalized Medicine
Studies report an association between the expression of HLA alleles and lamotrigine (LTG)-induced Stevens–Johnson syndrome (SJS). This systematic review and meta-analysis evaluates the association ...
22 May 2026 in Clinical Therapeutics
Technosphere insulin (TI) is an inhaled dry-powder insulin that has emerged as a potential alternative to subcutaneous rapid-acting insulin analogs (RAIA) for prandial glucose management. However, comprehensive evidence comparing TI with RAIA across both type 1 and type 2 diabetes mellitus remains limited. This systematic review and meta-analysis aim to compare the efficacy and safety of TI with RAIA. A comprehensive search was done by using predefined keywords and Boolean operators in three databases (PubMed, Scopus, Embase). Studies comparing TI with RAIA were included. The quality of included studies was assessed using the JBI Critical Appraisal Checklist. A random-effects model was used to compare the mean difference (MD) in HbA1c. Heterogeneity was assessed using I2 statistics, and publication bias was evaluated using funnel plots. Hypoglycaemia, weight change, and pulmonary safety were synthesized narratively due to heterogeneous outcome definitions. Six trials with a total of 1295 participants were included. No statistically significant difference in HbA1c reduction was observed between TI and RAIA (MD: -0.09; 95% confidence interval: -0.24 to 0.07; P = 0.28; I2 = 35%). In subgroup analyses, neither TI versus RAIA alone nor TI plus basal insulin versus RAIA plus basal insulin showed a statistically significant difference in HbA1c reduction. Narrative synthesis indicated lower hypoglycaemia rates and weight neutrality or modest weight benefit with TI. Cough, though mild and transient, was the most common adverse event, and pulmonary changes were small and reversible. TI provides comparable glycaemic control to RAIA, with no evidence of superior efficacy in HbA1c reduction. Therefore, the clinical value of inhaled insulin may depend less on glycaemic control and more on its role as a patient-preferred, noninvasive alternative offering a distinct risk-benefit balance, potentially enhancing adherence and quality of life in selected individuals. Limitations include the small number of eligible trials and heterogenous safety outcome reporting. Future research should prioritize long-term pulmonary safety.
11 February 2026 in Indian Journal of Tuberculosis
2 July 2026 in Medical Teacher
16 June 2026 in Anti-Infective Agents
Introduction: Antimicrobial Resistance (AMR) among gram-negative pathogens poses a major global threat, with limited new antibacterials approved. Cefepime/ enmetazobactam, a novel β-lactam/β-lactamase inhibitor, restores cefepime activity against extendedspectrum β-lactamase (ESBL)-producing Enterobacterales and other multidrug-resistant gramnegatives, offering an option for complicated Urinary Tract Infections (cUTIs). Methods: This narrative review synthesises phase 1–3 trials, in vitro surveillance, pharmacokinetic data, and network meta-analyses on cefepime/enmetazobactam versus comparators in cUTIs and related infections. Results: Enmetazobactam inactivates class A β-lactamases (KPC-2, CTX-M-15, SHV-1), boosting cefepime susceptibility from 2% to 98% against ESBL-Enterobacterales; activity is robust against AmpC-producers but limited against metallo-β-lactamases, OXA-types, Acinetobacter baumannii, and Stenotrophomonas maltophilia. In the phase 3 ALLIUM trial (n=1034), cefepime/enmetazobactam achieved superior composite cure rates versus piperacillin/ tazobactam (79.1% vs 58.9%; difference 21.2%) in cUTIs/pyelonephritis, including ESBLsubgroups. Network meta-analyses confirm outcomes comparable to carbapenems, with similar safety (mainly hepatic/infusion events). Discussion: Cefepime/enmetazobactam shows favourable outcomes as a newer agent for ESBLcUTIs compared to piperacillin/tazobactam, although evidence remains cUTI-focused with modest ESBL representation and spectrum gaps against key resistant pathogens. Pathogendirected use within stewardship is essential. Conclusion: Cefepime/enmetazobactam may contribute to AMR management for susceptible cUTIs/pyelonephritis and HAP/VAP, but its role beyond these indications will depend on further trials in high-risk ESBL/carbapenemase infections.